Tiziana Life Sciences Ltd
TLSAHealthcare|Biotechnology|GB
$0.69
+0.07 (+11.03%)
DCF Value
$0.01
Cash / Share
$0.02
Clinical Trials (15)
| Trial | Conditions | Phase | Status | Enrollment | Design | Drug |
|---|---|---|---|---|---|---|
| NCT06890923 Nasal Foralumab in Patients With Non-Active Secondary Progressive Multiple Sclerosis | Non-Active Secondary Progressive Multiple Sclerosis | P2 | Recruiting | 55 | Open-label | Foralumab TZLS-401 100 µg |
| NCT06292923 A Study of Nasal Foralumab in Non-Active Secondary Progressive Multiple Sclerosis Patients | Secondary Progressive Multiple Sclerosis | P2 | Active | 54 | RCT, Double-blind | Foralumab |
| NCT06489548 Assessment of Foralumab Safety and Modulation of Microglial Activation in Alzheimer's Disease | Dementia, Alzheimers Disease | P2 | Recruiting | 16 | RCT, Double-blind | Foralumab TZLS-401 50 µg, Foralumab TZLS-401 100 µg |
| NCT06868628 A Phase 2a Study of Foralumab Nasal in Patients With Multiple System Atrophy (MSA) | Multiple System Atrophy | P2 | Recruiting | 5 | Open-label | Foralumab Nasal |
| NCT03291249 Assessment of the Safety of Foralumab, an Oral Anti-CD3 Antibody, in Patients With NASH and T2DM | NASH - Nonalcoholic Steatohepatitis, NAFLD | P2 | Withdrawn | — | RCT, Double-blind | Foralumab, Omeprazole 20mg |
| NCT01011439 Phase II Study Of Oral PHA-848125AC In Patients With Thymic Carcinoma | Thymic Carcinoma | P2 | Terminated | 72 | Open-label | Milciclib Maleate |
| NCT05651269 Milciclib in Combination With Gemcitabine in Advanced NSCLC | NSCLC | P2 | Unknown | 28 | Open-label | Milciclib Dose: 150 mg/day Mode of administration: oral |
| NCT07688239 The BANYAN Trial, an ALS MyMatch Trial Evaluating Safety, Biomarker Activity, and Microglial Activation of Nasal Foralumab | ALS (Amyotrophic Lateral Sclerosis), ALS - Amyotrophic Lateral Sclerosis | P2 | By Invite | 44 | RCT, Double-blind | Foralumab Nasal, Placebo |
| NCT03109886 Study of Milciclib in Patients With Unresectable/Metastatic Hepatocellular Carcinoma | Hepatocellular Carcinoma | P2 | Completed | 31 | Open-label | Milciclib maleate |
| NCT04983446 In-patient COVID-19 Study of Intranasal Foralumab | Covid19, COVID-19 Lower Respiratory Infection | P2 | Withdrawn | — | RCT, Double-blind | Foralumab |
| NCT01301391 Study Of Oral PHA-848125AC In Patients With Malignant Thymoma Previously Treated With Multiple Lines Of Chemotherapy | Malignant Thymoma | P2 | Terminated | 30 | Open-label | Milciclib Maleate |
| NCT05028946 A Study of Oral Foralumab in Participants With Moderate to Severely Active Crohn's Disease | Crohn's Disease | P1 | Withdrawn | — | Open-label | Foralumab |
| NCT05029609 Phase 1b Multiple Ascending Dose Study of Foralumab in Primary and Secondary Progressive MS | Primary Progressive Multiple Sclerosis, Secondary Progressive Multiple Sclerosis | P1 | Withdrawn | — | RCT, Double-blind | Intranasal Foralumab Solution, Placebo |
| NCT06879067 Safety, Tolerability and Immune Effects of the Nasal Foralumab in Healthy Human Volunteers | Safety, Tolerability | P1 | Completed | 27 | RCT, Double-blind | Placebo, Foralumab Nasal |
| NCT06802328 Intermediate-Size Patient Population Expanded Access: Foralumab in Non-Active Secondary Progressive MS Patients | Non-Active Secondary Progressive Multiple Sclerosis | AVAILABLE | — | — | Foralumab TZLS-401 50 µg |